Natera, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven Leonard Chapman
- Full Time Employees
- 4,424
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 13011 McCallen Pass Building A Austin CA United States of America 78753
- IPO Date
- Jul 1, 2015
- CIK
- 0001604821
- Website
- natera.com
- Similar Companies
- Business
- Natera, Inc. (NTRA) is a global leader in cell-free DNA (cfDNA) testing, specializing in noninvasive molecular diagnostics for oncology, women's health, and organ health. Founded in 2004 and headquartered in Austin, Texas, the company operates CAP-accredited and CLIA-certified laboratories in Austin, Texas, and San Carlos, California, with a global presence including facilities in the Netherlands and partnerships extending services to numerous countries worldwide. Natera leverages proprietary technology combining novel molecular biology and bioinformatics to detect genetic material from blood samples, enabling early risk assessment, recurrence detection, and personalized treatment decisions for clinicians and patients. The company's core offerings span women's health tests including Panorama, a non-invasive prenatal test (NIPT) screening for fetal chromosomal abnormalities such as Down syndrome with positive predictive value reporting; Horizon, advanced carrier screening for hundreds of genetic conditions; Vistara, single-gene NIPT for 25 additional conditions; Anora, a miscarriage analysis test; Spectrum, preimplantation genetic testing for IVF embryos; and Empower for hereditary cancer risk. In oncology, Natera provides Signatera, a personalized circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) monitoring, recurrence detection, and treatment response evaluation across cancers like colorectal, bladder, lymphoma, and multiple myeloma; Altera for tumor genomic profiling to identify somatic mutations and clinical trials; Latitude, a tissue-free MRD test; and Empower for germline mutations. Organ health solutions feature Prospera, a donor-derived cfDNA test for kidney transplant rejection assessment. Recent developments include the launch of Signatera Genome, a genome-designed MRD assay achieving Medicare coverage; Latitude Tissue-Free MRD; Fetal Focus single-gene NIPT with an expanded version forthcoming; and a Panorama vanishing twin workflow. Natera raised its 2025 revenue guidance to $2.18-$2.26 billion following strong Q3 2025 results with record revenues and oncology test volume growth of 46.1% year-over-year, alongside plans for seven new MolDX submissions potentially worth $250-$300 million in gross profit. Strategic partnerships with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. enhance genetic testing capabilities and market expansion in precision medicine, while new data from trials like IMvigor011 and upcoming presentations at the 2025 American Society of Hematology meeting underscore ongoing clinical validation.
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
Why Natera Is My Favorite Stock Idea for the Rest of 2026
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
Baron Health Care Fund Q1 2026 Portfolio Activity
Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results
Natera Expands Austin Operations With New Sequencing Facility
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth